ESMO Clinical Practice Guidelines
ESMO Consensus Conferences
ESMO Pocket & Mobile Guidelines
ESMO Guides for Patients
ESMO first began to work on the development of guidelines in 1999 in order to help define the minimum standards of medical oncology practice for Eastern European countries.

From 2001-2005 the ESMO Minimum Clinical Recommendations were published.

In 2006 ESMO started to produce the ESMO Clinical Recommendations addressing a wider audience.

In 2007 the Consensus Conference derived guidelines were established.

Since 2010 they are called ESMO Clinical Practice Guidelines.
The Structure Of the ESMO GLWG

Editorial Board
Chairman & Co-Chairman
2 Members
1 ESMO Officer

Subject Editors
1. Breast Cancer
2. Gynaecological Cancer
3. Haematological Malignancies
4. Lung Cancer
5. Head and Neck Cancer
6. Urogenital Cancer
7. Upper and lower GI tract cancers
8. Pancreato-hepatobiliary cancers
9. Sarcoma & GIST
10. Supportive Care
11. Palliative Care
12. Rare Tumors

Reviewers
5 ESMO Faculty Members per Topic on a multidisciplinary platform

Authors
(Multidisciplinary)
What kind of guidelines?

The Short Sized Guidelines (CPG)

- Average number of pages: 5 (2-13)
- Evidence based
- Disease or topic oriented
- Available on the ESMO website / OncologyPRO
- Only those requiring update are published in Annals of Oncology
Guidelines: topics & authors selection process

1. **GLWG annual strategy meeting**
2. **Identification of Guidelines requiring update and new titles**
3. **Subject Editors (SEs) propose lead authors**
4. **GLWG Editorial Board approve lead authors**
5. **SEs and lead authors identify co-authors (4/5 in total, multidisciplinary)**
6. **Manuscript & author information included in on-line system**
7. **Author invitations sent via on-line system (including deadlines and template)**
8. **Authors accept invitations & deadlines (or repeat steps 3-6)**
Clinical Practice Guidelines Template

- **Authorship:**
  - 3-5 experts from different institutions and different countries in Europe.
  - Multidisciplinary including medical oncologists, a surgical oncologist and a radiation oncologist (or other disciplines if appropriate).

- **Page extent:**
  - 2500-4500 words

- **References:**
  - 20-30 most recently published RCT, meta-analyses or systematic reviews.

- **Levels of Evidence & Grades of Recommendation**
  - ESMO Grading (adapted from the Infectious Diseases Society of America System)

- **Thematic sections:**
  - Incidence & epidemiology
  - Diagnosis & pathology/molecular biology
  - Staging and Risk Assessment
  - Management of local/locoregional disease
  - Management of advanced/metastatic disease
  - Personalised Medicine
  - Follow-up and long-term implications
Authors review literature, grade evidence and produce 1st draft

SEs select 5 reviewers per manuscript (ESMO faculty preference)

Reviewers submit their comments via on-line system

Review step repeated with revised manuscript until SE sign-off

Authors address review comments in revised manuscript

Review comments compiled, anonymised and sent to authors

Final sign-off by GLWG Chair

Manuscripts sent to Annals of Oncology for production

Copy-editing & proof review (SEs & Chair). Approved for print by ESMO.
Dissemination and promotion

Available:
- In an annual supplement of Annals of Oncology and on-line (open access)
- On the ESMO website (www.esmo.org)
- On the OncologyPRO website (oncologypro.esmo.org)

Translated:
- In collaboration with National Cancer Societies (Russian, Georgian)
- With permission from Oxford University Press (13 languages to date)

Presented:
- During Guidelines Interactive Sessions (each year since 2002).
- To audiences of up to 3200 attendees.
- With positive feedback (2011):
  - >75% of the audience had consulted the ESMO CPGs in the past year
  - >90% thought the ESMO Guidelines are a helpful source of advice
  - >85% thought the ESMO Guidelines are good educational tools
What kind of guidelines?

Consensus Conference Derived Guidelines

- To address pre-selected questions to 30-40 multidisciplinary experts on specific tumor types
- 1-2 days meeting
- Funded by ESMO or other professional networks
- Update every 2-5 years
- Published in Annals of Oncology
<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Organizer</th>
<th>Panel Members</th>
<th>No Countries</th>
<th>Multidisciplinarity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct 2007</td>
<td>Soft tissue sarcomas GIST</td>
<td>Conticancet</td>
<td>45</td>
<td>16</td>
<td>PA, MO, SO, RO</td>
</tr>
<tr>
<td>May 2008</td>
<td>Seminoma Non-seminoma</td>
<td>ESMO</td>
<td>66</td>
<td>18</td>
<td>-</td>
</tr>
<tr>
<td>May 2009</td>
<td>Communication Skills</td>
<td>Swiss, Cancer League</td>
<td>45</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>June 2009</td>
<td>Antiemetics</td>
<td>MASCC/ESMO</td>
<td>23</td>
<td>10</td>
<td>CM, ON, PHARM, MP, MO, SO, RO</td>
</tr>
<tr>
<td>Nov 2009</td>
<td>Soft tissue sarcomas GIST Bone Sarcomas</td>
<td>Conticanet, Eurobonet</td>
<td>44</td>
<td>15</td>
<td>-</td>
</tr>
<tr>
<td>May 2010</td>
<td>NSCLC SCLC</td>
<td>ESMO, San Salvatore Foundation</td>
<td>38</td>
<td>15</td>
<td>PA, MD, MO, SO, RO</td>
</tr>
<tr>
<td>Sept 2010</td>
<td>Colorectal cancer</td>
<td>ESMO</td>
<td>37</td>
<td>22</td>
<td>PA, MO, SO, RO</td>
</tr>
<tr>
<td>June 2011</td>
<td>Malignant Lymphoma</td>
<td>ESMO</td>
<td>47</td>
<td>14</td>
<td>MO, HEM</td>
</tr>
<tr>
<td>Nov 2011</td>
<td>Prostate Cancer</td>
<td>ESMO</td>
<td>25</td>
<td>16</td>
<td>UR, MO, SO, RO</td>
</tr>
<tr>
<td>Jan 2012</td>
<td>Soft-tissue Sarcoma GIST Bone Sarcoma</td>
<td>ESMO</td>
<td>41</td>
<td>16</td>
<td>EPI, PA, PHARM, HEM, MO, SO, RO</td>
</tr>
</tbody>
</table>
Consensus Conference Flowchart

**GLWG:**
- Chooses 2 Consensus Conferences (CC) per year based on proposals from Subject Editors (SE)
- Appoints CC Chair and SE as co-Chair

**2 CHAIRS:**
- Form CC (max. 30 members)
- Collect COIs
- Define Subtopics, each assigned to a Working Group (WG) with Coordinator
  1 MONTH

**PREPARATION MEETING:**
- Chairs & WG Coordinators meet to select contributors and define Questions
  3-6 MONTHS PRIOR TO CONFERENCE
- (2-3 MONTHS ALLOWED FOR CC INVITATION PROCESS)
  3 MONTHS

**EACH WORKING GROUP:**
- Search strategy and Rules
- Database Search
- Study of Evidence
- Report on Questions & evidence review prepared and forwarded to Chairs

**CONSENSUS CONFERENCE:**
- Working Group Discussion Phase
- Joint Presentation Phase
- Conclusion Phase (Chairs)
- Meeting with Chairs & WG Coordinators to discuss next steps and timelines
  2 DAYS

**PUBLICATION:**
- Production
- Publication in Annals of Oncology
  1-3 MONTHS

**WRITING UP (CHAIRS):**
- Write FULL VERSION and POCKET VERSION of manuscript
- Circulate to all CC contributors for comment
- Hand over final manuscript to GLWG for approval
  2-3 MONTHS

**EACH WORKING GROUP:**
All Subcommittees are requested to hand over a draft manuscript with Questions & Recommendations
  1 MONTH
ESMO collaborates with other organisations in the development of Clinical Practice Guidelines and Consensus Statements:

- MASCC: CPG on Prevention of chemotherapy an radiotherapy-induced nausea & vomiting
- EHNS & ESTRO: CPGs on Head & Neck tumors
- ESDO: CPGs on Pancreatic adenocarcinoma and Hepatocellular carcinoma
- EONS: CPG on Chemotherapy Extravasation
- Conticanet & Eurobonet: Consensus conferences on Sarcoma & GIST
- ESO: Consensus conference on Advanced Breast Cancer (ABC2)
- ESSO & ESTRO: pilot project to develop CPG on Gastric Cancer and Anal Cancer for publication in 2013
Abridged & mobile versions

ESMO Pocket Guidelines
- Pilot project in 2011: Lung cancer & Mesothelioma
- Six pocket guidelines for 2012 distributed during the ESMO Congress:
  - Breast Cancer
  - Lung cancer
  - Urogenital Cancer
  - NETs & GIST
  - Sarcoma
  - Supportive Care

New mobile library: ESMO Cancer Guidelines
- Available for Android, iPhone and iPad
- All six 2012 pocket guidelines included
- Additional title to be added later this year: Head & Neck Cancer
Guides for Patients* based on ESMO Clinical Practice Guidelines, prepared in a format your patients can easily understand

*in collaboration with Reliable Cancer Therapies

- The main goal of the project is to constantly help patients and their relatives to better understand the nature of different types of cancer and appreciate the best available treatment choices.

- Patient guides are available in different languages (English, Dutch, French, Spanish). Other languages will be added.

- Download from [www.esmo.org](http://www.esmo.org) or [www.reliablecancertherapies.com](http://www.reliablecancertherapies.com)

- **Online:** AML, bladder cancer, breast cancer, CML, endometrial cancer, esophageal cancer, liver cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.

- Soon to be included in the ESMO Cancer Guidelines mobile library
Thank you